<DOC>
	<DOC>NCT02597257</DOC>
	<brief_summary>The investigators conducted a randomized, Double blind, and Controlled Study to evaluate the Efficacy and safety of Lidocaine Infusion Treatment in Management of Neuropathic pain.</brief_summary>
	<brief_title>Efficacy and Safety of Lidocaine Infusion Treatment in Management of Neuropathic Pain</brief_title>
	<detailed_description>The investigators expect pain improvement after treatment with 3 mg/kg of lidocaine, continuously infused in normal saline 250 ml.</detailed_description>
	<mesh_term>Neuralgia</mesh_term>
	<mesh_term>Peripheral Nervous System Diseases</mesh_term>
	<mesh_term>Polyneuropathies</mesh_term>
	<mesh_term>Neuralgia, Postherpetic</mesh_term>
	<mesh_term>Diabetic Neuropathies</mesh_term>
	<mesh_term>Lidocaine</mesh_term>
	<criteria>postherpetic neuralgia, diabetic polyneuropathy, peripheral neuropathy NRS score &gt; 4 stable oral medication during the 1 month trial period volunteers with informed consent pregnancy, breastfeeding, possibility of pregnancy pain from causes other than upper 3 indications hypersensitivity to lidocaine or other local anesthetics important disease of heart, kidney, liver or incurable disease that may affect the assessment of adverse effects, or may interfere with the completion of study severe conduction block history of other interventions that may affect the study Enrollment in other clinical trials within 30 days otherwise not suitable to study</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>November 2015</verification_date>
	<keyword>Lidocaine infusion therapy</keyword>
</DOC>